- In January 2025, Roche announced positive Phase III trial results for a new bispecific antibody targeting cervical tumor microenvironment, showing a 27% improvement in progression-free survival over standard care
- In October 2024, GSK received EMA approval for its novel HPV-targeted immunotherapy for second-line cervical cancer treatment, expanding its oncology pipeline in Europe
- In August 2024, AstraZeneca launched a global clinical trial program for its next-generation PARP inhibitor in cervical cancer, involving over 20 countries and 3,000 patients
- In March 2024, Pfizer expanded its cervical cancer collaboration with academic institutions in India for biomarker-based treatment approaches and real-world data collection
- In November 2023, Merck & Co. partnered with a leading diagnostics firm to co-develop companion diagnostics for stratifying cervical cancer patients based on PD-L1 expression
